A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

Key Inclusion Criteria:

• Completed an applicable parent study: GS-US-292-0106, GS-US-380-1474,GS-US-311-1269, or GS-US-216-0128, and gave consent to study participation.

Key Exclusion Criteria:

• Individuals planning to switch to B/F/TAF on Day 1 with plasma HIV RNA ≥ 50copies/mL during the last parent study visit prior to screening/Day 1 visit.

• Note: individuals planning to switch after Day 1 must not have plasma HIV RNA ≥ 50 copies/mL (or detectable HIV-1 RNA level according to the local assay beingused if the limit of detection is ≥ 50 copies/mL).

• Individuals planning to switch to B/F/TAF with any ongoing Grade 3 or 4 drug-relatedAE or clinically relevant Grade 3 or 4 drug-related laboratory abnormality (confirmed on repeat) related to any component of B/F/TAF prior to treatment switch.

• For those on B/F/TAF or planning to switch to B/F/TAF: previous treatmentdiscontinuation of any component of B/F/TAF due to toxicity or intolerance.

• For those planning to switch to B/F/TAF: known hypersensitivity to any component ofthe study drug, its metabolites, or formulation excipients.

• Ongoing treatment with or prior use of any prohibited medications.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.